Analyst consensus rating
Autolus Therapeutics Analyst Rating: none
Direct answer
Autolus Therapeutics's consensus rating is none.
8 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $8.73.
Forecast evidence checked September 5, 2026.
Get free Autolus Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $2.24
- Average price target
- $8.73
- High price target
- $11.00
- Low price target
- $5.00
- Low target gap
- +123.2%
- Target upside
- +289.5%
- High target gap
- +391.1%
- Target range width
- 267.9%
- Consensus rating
- none
- Analysts
- 8
- Evidence date
- September 5, 2026
- Valid through
- September 12, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Autolus Therapeutics?
Autolus Therapeutics has a verified none consensus. The same dataset has an average price target of $8.73.
How far are Autolus Therapeutics's low and high targets from the recorded price?
The low target implies +123.2%, while the high target implies +391.1%.
How many analysts are included in Autolus Therapeutics's consensus?
The verified consensus includes 8 analysts.
How is Autolus Therapeutics's target upside or downside calculated?
The average target of $8.73 is divided by the recorded price of $2.24, then one is subtracted to produce +289.5%. This does not guarantee a future return.
When was Autolus Therapeutics's analyst forecast verified?
The data was verified on 2026-09-05. The dataset is valid through 2026-09-12.